Funding for this research was provided by:
National Institutes of Health (T32DK007418, F32HD91025, K08DE028946, NIH R01AR073015)
Department of Medicine, University of California, San Francisco (REAC Summer Explore fellowship)
Received: 7 February 2020
Accepted: 25 March 2020
First Online: 3 April 2020
Ethics approval and consent to participate
: The phase 2 palovarotene study was sponsored by Clementia, an Ipsen company, and approved by the Institutional Review Board at the University of California, San Francisco. The participant involved in the study gave informed consent and signed an informed consent form.
: Written consent to publish this information was obtained from the patient.
: ECH serves in a volunteer capacity on the registry advisory board of the International Fibrodysplasia Ossificans Progressiva Association; on the International Clinical Council on FOP, and on the Fibrous Dysplasia Foundation Medical Advisory Board. ECH received prior research support through his institution from Regeneron Pharmaceuticals. ECH and KW receive clinical trials research support through their institution from Clementia, an Ipsen company. These pose no conflicts for this study.